These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30982082)

  • 1. The future of a partially effective HIV vaccine: assessing limitations at the population level.
    Selinger C; Dimitrov DT; Welkhoff PA; Bershteyn A
    Int J Public Health; 2019 Jul; 64(6):957-964. PubMed ID: 30982082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa.
    Selinger C; Bershteyn A; Dimitrov DT; Adamson BJS; Revill P; Hallett TB; Phillips AN; Bekker LG; Rees H; Gray G
    Vaccine; 2019 Apr; 37(16):2258-2267. PubMed ID: 30890385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential impact of RV144-like vaccines in rural South Africa: a study using the STDSIM microsimulation model.
    Hontelez JA; Nagelkerke N; Bärnighausen T; Bakker R; Tanser F; Newell ML; Lurie MN; Baltussen R; de Vlas SJ
    Vaccine; 2011 Aug; 29(36):6100-6. PubMed ID: 21703321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand.
    Andersson KM; Stover J
    Vaccine; 2011 Aug; 29(36):6092-9. PubMed ID: 21703322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: examining the RV144 trial results.
    Andersson KM; Paltiel AD; Owens DK
    Vaccine; 2011 Aug; 29(36):6107-12. PubMed ID: 21736912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of a modestly effective HIV vaccine in the United States.
    Long EF; Owens DK
    Vaccine; 2011 Aug; 29(36):6113-24. PubMed ID: 21510996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study.
    de Montigny S; Adamson BJS; Mâsse BR; Garrison LP; Kublin JG; Gilbert PB; Dimitrov DT
    Sci Rep; 2018 Apr; 8(1):6066. PubMed ID: 29666455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
    Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
    Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
    Laher F; Moodie Z; Cohen KW; Grunenberg N; Bekker LG; Allen M; Frahm N; Yates NL; Morris L; Malahleha M; Mngadi K; Daniels B; Innes C; Saunders K; Grant S; Yu C; Gilbert PB; Phogat S; DiazGranados CA; Koutsoukos M; Van Der Meeren O; Bentley C; Mkhize NN; Pensiero MN; Mehra VL; Kublin JG; Corey L; Montefiori DC; Gray GE; McElrath MJ; Tomaras GD
    PLoS Med; 2020 Feb; 17(2):e1003038. PubMed ID: 32092060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How low can you go: the impact of a modestly effective HIV vaccine compared with male circumcision.
    Kaldor JM; Wilson DP
    AIDS; 2010 Oct; 24(16):2573-8. PubMed ID: 20829677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.
    Gray GE; Moodie Z; Metch B; Gilbert PB; Bekker LG; Churchyard G; Nchabeleng M; Mlisana K; Laher F; Roux S; Mngadi K; Innes C; Mathebula M; Allen M; McElrath MJ; Robertson M; Kublin J; Corey L;
    Lancet Infect Dis; 2014 May; 14(5):388-96. PubMed ID: 24560541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa.
    Amirfar S; Hollenberg JP; Abdool Karim SS
    J Acquir Immune Defic Syndr; 2006 Oct; 43(2):219-25. PubMed ID: 16951648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential future impact of a partially effective HIV vaccine in a southern African setting.
    Phillips AN; Cambiano V; Nakagawa F; Ford D; Lundgren JD; Roset-Bahmanyar E; Roman F; Van Effelterre T
    PLoS One; 2014; 9(9):e107214. PubMed ID: 25207973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.
    Gray GE; Allen M; Moodie Z; Churchyard G; Bekker LG; Nchabeleng M; Mlisana K; Metch B; de Bruyn G; Latka MH; Roux S; Mathebula M; Naicker N; Ducar C; Carter DK; Puren A; Eaton N; McElrath MJ; Robertson M; Corey L; Kublin JG;
    Lancet Infect Dis; 2011 Jul; 11(7):507-15. PubMed ID: 21570355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk compensation after HIV-1 vaccination may accelerate viral adaptation and reduce cost-effectiveness: a modeling study.
    Peebles K; Mittler JE; Goodreau SM; Murphy JT; Reid MC; Abernethy N; Gottlieb GS; Barnabas RV; Herbeck JT
    Sci Rep; 2021 Mar; 11(1):6798. PubMed ID: 33762616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Case for Adolescent HIV Vaccination in South Africa: A Cost-Effectiveness Analysis.
    Moodley N; Gray G; Bertram M
    Medicine (Baltimore); 2016 Jan; 95(4):e2528. PubMed ID: 26825890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expected epidemiological impact of the introduction of a partially effective HIV vaccine among men who have sex with men in Australia.
    Gray RT; Ghaus MH; Hoare A; Wilson DP
    Vaccine; 2011 Aug; 29(36):6125-9. PubMed ID: 21703320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expected epidemiological impacts of introducing an HIV vaccine in Thailand: a model-based analysis.
    Schneider K; Kerr CC; Hoare A; Wilson DP
    Vaccine; 2011 Aug; 29(36):6086-91. PubMed ID: 21723902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Participants' characteristics and motivations to screen for HIV vaccine and monoclonal antibody trials in KwaZulu-Natal, South Africa.
    Hanass-Hancock J; Carpenter B; Reddy T; Nzuza A; Gaffoor Z; Goga A; Andrasik M
    Trials; 2021 Dec; 22(1):897. PubMed ID: 34895272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential impact of an HIV vaccine with limited protection on HIV incidence in Thailand: a modeling study.
    Nagelkerke NJ; Hontelez JA; de Vlas SJ
    Vaccine; 2011 Aug; 29(36):6079-85. PubMed ID: 21718745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.